

# Regional bulletin for the availability of antimalarial medicines: First Quarter 2014

Volume 1 Number 1  
2014



Plataforma Regional sobre  
Acceso e Innovación para  
Tecnologías Sanitarias  
PRATS

[www.paho.org/prais](http://www.paho.org/prais)

This bulletin is developed through a collaborative effort between the National Malaria Control Programs of the Region of the Americas, PAHO/WHO and SIAPS/USAID to facilitate sharing of information between countries in the Americas. The objectives of the bulletin are to increase awareness of stocks of antimalarial medicine, generate stock out alerts and promote exchanges and donations of antimalarial medicines between countries.

This bulletin is based on information provided by countries in South and Central America who participate in the Amazon Malaria Initiative (AMI) and are members of the Amazon Network for the Surveillance of Antimalarial Drug Resistance (RAVREDA). The bulletin offers information on the availability of medicines in central and regional medical stores that allow countries' decision makers to assure uninterrupted supply.

The following tables detail the availability of antimalarial medicines for each country. Stock out is considered zero availability in the storerooms.

The indicator of months of availability is calculated by each country by dividing the availability of medicines by the average monthly consumption or distribution. The average consumption is found by dividing the distribution or consumption over the previous year by 12.

This fourth bulletin includes information from nine countries, five from South America and four from Central America. Five countries sent central and regional level data.



**USAID**  
FROM THE AMERICAN PEOPLE



Availability of medicines for the first quarter, 2014

Medications			BELIZE					BRASIL					COLOMBIA				
			Central			Department		Central			Department		Central			Department	
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet					1	1,740	1.12			1	1,140	2.10			
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet					1	3,990	1.93			1	6,144	2.30			
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet					1	2,610	1.19			1	51,390	7.10			
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	0.00	0.00	0.00	0.00	1	34,980	8.22			1	240,576	4.90		
	005	Artesunate 50 mg tablet															
	006	Artesunate 100 mg tablet															
	007	Artesunate 250 mg tablet															
	008	Artesunate+ SP (Children)															
	009	Artesunate+ SP (Adolescent)															
	010	Artesunate+ SP (Adults)															
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.						1	1,860	41.33							
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.						1	2,600	54.17							
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.						1	2,690	32.02							
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.						1	15,670	198.35							
	015	Mefloquine 250 mg tablet	0	800	16.00												
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet															
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	111,290	11.13	21,800	4.07	1	1,401,500	5.09			1	995,570	14.90		
	018	Chloroquine phosphate 100 mg tablet	0	12,000													
	019	Primaquine phosphate 5 mg tablet	1	0	0.00	0	0.00	1	667,000	5.18			1	236,355	12.8		
	020	Primaquine phosphate 7.5 mg tablet															
	021	Primaquine phosphate 15 mg tablet	1	6,000	85.71	5,424	77.49	1	2,618,500	7.95			1	122,240	1.40		
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules						1	52,986	59.60							
	023	Artesunate rectal 50 mg										1	6,227	19.50			
	024	Artesunate rectal 100 mg															
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule						1	43,140	22.63			1	2,088	10.90		
	026	Clindamycin Hydrochloride 300 mg Capsule						1	0	0.00							
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable						1	0	0.00							
	028	Clindamycin Hydrochloride 150 mg Capsule															
	029	Clindamycin 75mg/5mL suspension															
	030	Doxycycline 100 mg Capsule						1	0	0.00							
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable						1	0	0.00			1	2,608	8.70		
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable															
	033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable															
	034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable															
	035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable															
	036	Quinine Sulfate 300mg tablet	0	200	0.00								1	168,536	65.60		
	037	Quinine Sulfate 500 mg tablet						1	96,500	12.63							

Availability of medicines for the first quarter, 2014

Medications			ECUADOR					HONDURAS					NICARAGUA					
			Central			Department		Central			Department		Central			Department		
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet	1	274	204.22	91	67.83											
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet	1	283	210.93	168	125.22											
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet	1	87	64.84	247	184.10											
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	18	1.34	215	16.02											
	005	Artesunate 50 mg tablet																
	006	Artesunate 100 mg tablet																
	007	Artesunate 250 mg tablet																
	008	Artesunate+ SP (Children)																
	009	Artesunate+ SP (Adolescent)																
	010	Artesunate+ SP (Adults)																
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.																
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.																
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.																
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.																
	015	Mefloquine 250 mg tablet																
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet							1	0	0.00							
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	36,635	202.59	16,608	91.84	1	1,073,157	34.57			1	945,685	4.69	782,883	3.89	
	018	Chloroquine phosphate 100 mg tablet																
	019	Primaquine phosphate 5 mg tablet						1	0	0.0			1	874,512	6.57	432,694	3.35	
	020	Primaquine phosphate 7.5 mg tablet	1	162	6.40	5,837	230.56											
	021	Primaquine phosphate 15 mg tablet	1	3,441	13.59	29,956	118.33	1	661,395	27.98			1	399,822	2.20	448,900	2.47	
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules																
	023	Artesunate rectal 50 mg																
	024	Artesunate rectal 100 mg																
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule	1	32	2.39	321	23.93											
	026	Clindamycin Hydrochloride 300 mg Capsule	1	1,426	106.29	574	42.78						1	162,710	1.21	180,058	1.34	
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable																
	028	Clindamycin Hydrochloride 150 mg Capsule																
	029	Clindamycin 75mg/5mL suspension																
	030	Doxycycline 100 mg Capsule																
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable																
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable																
	033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable																
	034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable							1	0	0.00			1	1,349	16.45	342	4.12
	035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable																
	036	Quinine Sulfate 300mg tablet	1	439	7.79	2,095	37.18	1	0	0.00								
	037	Quinine Sulfate 500 mg tablet																

Availability of medicines for the first quarter, 2014

Medications			PANAMA				PERU				SURINAME						
			Central		Department		Central		Department		Central		Departmental				
			Original medication based on the Standard Treatment Guidelines (1=yes, 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	Original medication based on the Standard Treatment Guidelines (1=yes, 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	Original medication based on the Standard Treatment Guidelines (1=yes, 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet	1	180	7.50	0	0.00						1	282	47.00		
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet	1	360	15.00	0	0.00						1	1,704	142.00		
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet	1	540	22.50	0	0.00						1	2,070	115.00		
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	670	27.92	710	29.58						1	18,696	77.90		
	005	Artesunate 50 mg tablet						1	151,338	455.84	68,538	104.48					
	006	Artesunate 100 mg tablet											1	0	0.00		
	007	Artesunate 250 mg tablet						1	17,084	17.20	33,194	16.92					
	008	Artesunate+ SP (Children)															
	009	Artesunate+ SP (Adolescent)															
	010	Artesunate+ SP (Adults)															
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.															
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.															
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.															
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.											1	1,230	205.00		
	015	Mefloquine 250 mg tablet						1	516	0.26	21,625	5.52	1	1,800	1,800.00		
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet	0	9,000													
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	142,000	2.45	34,810	14.18	1	95,690	4.15	415,868	12.29	1	66,900	669.00		
	018	Chloroquine phosphate 100 mg tablet															
	019	Primaquine phosphate 5 mg tablet	1	15,000	3.00	0	0.00						1	0	0.00		
	020	Primaquine phosphate 7.5 mg tablet						1	0	0.00	0	0.00	1	14,900	43.82		
	021	Primaquine phosphate 15 mg tablet	1	370,000	12.33	52,920	15.12	1	77,150	2.39	429,020	9.06	1	0	0.00		
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules						0	84				1	192	64.00		
	023	Artesunate rectal 50 mg															
	024	Artesunate rectal 100 mg															
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule									691		1	289	72.25		
	026	Clindamycin Hydrochloride 300 mg Capsule															
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable															
	028	Clindamycin Hydrochloride 150 mg Capsule															
	029	Clindamycin 75mg/5mL suspension															
	030	Doxycycline 100 mg Capsule															
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable															
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable															
	033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable															
	034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable						1	11,361	206.56	243	2.25					
	035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable															
	036	Quinine Sulfate 300mg tablet						1	3,000	16.04	4,787	12.90					
	037	Quinine Sulfate 500 mg tablet															

Source: Consolidated National Report from Countries

## Indicators reported for the first quarter, 2014

INDICATORS	Belice		Brasil		Colombia		Ecuador		Honduras		Nicaragua		Panamá		Perú		Suriname	
	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart
No. of department warehouses that report medication availability data.		7						9				17		14		33		
% of regional stores that report stockout in one or more antimalarials required by the Standard Treatment Guidelines (STG).		100%						73%				6%		7%		93%		
Number of medicines required in the Standard Treatment Guidelines (STG)	4	4	18		11		10	10	6		5	5	7	7	8	8	13	
Number of STG medicines that are available.	2	2	14		11		10	10	2		5	5	7	3	7	7	10	
% of STG medications available	50%	50%	78%		100%		100%	100%	33%		100%	100%	100%	43%	88%	88%	77%	
% of STG medications not available	50%	50%	22%		0%		0%	0%	67%		0%	0%	0%	57%	13%	13%	23%	
% of STG medications with availability less than the minimum security stock (3 months)	50%	50%	39%		27%		20%	0%	67%		40%	40%	29%	57%	38%	25%	23%	
% of STG medications which are overstocked (more than 24 months of availability)	25%	25%	28%		9%		50%	80%	33%		0%	0%	14%	14%	25%	13%	77%	

This bulletin was elaborated within the framework of AMI/RAVREDA with assistance from PAHO/WHO, specifically the Medicines and Health Technologies (HSS/MT) unit and the Regional Malaria Program (CHA/VT) and the USAID funded program Systems for Improved Access to Pharmaceuticals and Services (SIAPS). Data for the report was sent by the National Malaria Control Programs of the participating countries. The consolidation and editing of the bulletin was completed by the regional team of the PAHO/WHO Strategic Fund, which utilized the previous format developed by DIGEMID and SIAPS/USAID as a reference



**USAID**  
FROM THE AMERICAN PEOPLE

**SIAPS**  
Systems for Improved Access  
to Pharmaceuticals and Services